![NICE's thumbs-up on Lilly's migraine med Emgality leaves rivals from Novartis and Teva in the dust | Fierce Pharma NICE's thumbs-up on Lilly's migraine med Emgality leaves rivals from Novartis and Teva in the dust | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1605712597/emgality.jpg/emgality.jpg?VersionId=s53qa5HDrYH1evXCzU6Ui_OIvBCIl4dP)
NICE's thumbs-up on Lilly's migraine med Emgality leaves rivals from Novartis and Teva in the dust | Fierce Pharma
![Cost-per-remitter with esketamine nasal spray versus standard of care for treatment-resistant depression | Journal of Comparative Effectiveness Research Cost-per-remitter with esketamine nasal spray versus standard of care for treatment-resistant depression | Journal of Comparative Effectiveness Research](https://www.futuremedicine.com/cms/10.2217/cer-2020-0276/asset/images/medium/figure2.gif)
Cost-per-remitter with esketamine nasal spray versus standard of care for treatment-resistant depression | Journal of Comparative Effectiveness Research
![Cost-per-remitter with esketamine nasal spray versus standard of care for treatment-resistant depression | Journal of Comparative Effectiveness Research Cost-per-remitter with esketamine nasal spray versus standard of care for treatment-resistant depression | Journal of Comparative Effectiveness Research](https://www.futuremedicine.com/cms/10.2217/cer-2020-0276/asset/images/medium/figure3a.gif)
Cost-per-remitter with esketamine nasal spray versus standard of care for treatment-resistant depression | Journal of Comparative Effectiveness Research
![Disturbo depressivo grave. Esketamina spray nasale riduce rapidamente i sintomi depressivi - SOCIALFARMA Disturbo depressivo grave. Esketamina spray nasale riduce rapidamente i sintomi depressivi - SOCIALFARMA](https://www.socialfarma.it/wp-content/uploads/2018/12/spray-nasale.jpg)